Cryoport Reports Strong Q1 Results, Raises Full-Year Revenue Guidance to $192M-$196M
Summary
Cryoport reported a 16% year-over-year revenue increase in Q1 2026, significantly improved adjusted EBITDA, and raised its full-year revenue guidance to $192 million - $196 million.
Key Events
-
Strong Q1 Revenue Growth
Total revenue for Q1 2026 increased 16% year-over-year to $47.8 million, driven by 18% growth in Life Sciences Services and 15% in Life Sciences Products.
-
Raised Full-Year Revenue Guidance
The company raised its full-year 2026 revenue guidance to a range of $192 million to $196 million, reflecting increased confidence in continued growth.
-
Improved Profitability Metrics
Adjusted EBITDA from continuing operations significantly improved from a negative $2.8 million in Q1 2025 to a negative $0.6 million in Q1 2026, indicating progress towards profitability.
-
Expanding Commercial & Clinical Support
Cryoport now supports a record 766 global clinical trials and 21 commercially approved cell and gene therapies, with commercial CGT revenue growing 26% year-over-year.
Analysis
Cryoport delivered a strong first quarter, exceeding expectations with significant revenue growth across all segments and a notable improvement in adjusted EBITDA, signaling progress towards profitability. The decision to raise full-year revenue guidance reflects increased confidence in their operational momentum and market position, particularly within the commercial cell and gene therapy sector. This positive financial update, coupled with strategic operational milestones like new global supply chain centers, suggests a robust outlook for the company.
At the time of this filing, CYRX was trading at $10.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $512.5M. The 52-week trading range was $5.31 to $11.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.